Jubilant Pharmova Strengthens Compliance

has successfully cleared a USFDA Post-marketing Adverse Drug Experience (PADE) inspection at its US subsidiary, Jubilant Cadista Pharmaceuticals Inc., with zero observations on September 19, 2025—an important validation of its strong quality and compliance framework. Alongside this milestone, the company reported its Q1 FY26 results on July 29, posting revenue of ₹1,901 crore, up 9.2% from ₹1,732 crore last year, driven by stronger momentum in CRDMO, sterile injectables, and generics. EBITDA rose 14% to ₹302 crore, with margins improving to 15.3% versus 14.5% a year ago, reflecting better execution and operating efficiency. While profits moderated due to a high base, the business demonstrated resilience and growth across its diverse segments, including Radiopharma, Allergy Immunotherapy, and Novel Drugs. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.